Immunoglobulin E news

All news on Immunoglobulin E (also known as IgE): plants, production capacities, investments and involved companies.

3 March 2026

GSK Finalizes RAPT Therapeutics Acquisition

GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.

Who will be producing Immunoglobulin E in the future?

Find out with chemXplore Analytics